Last reviewed · How we verify
BPaQ
BPaQ is a prodrug formulation designed to improve the oral bioavailability and therapeutic delivery of its active moiety.
At a glance
| Generic name | BPaQ |
|---|---|
| Also known as | Bedaquiline, Pretomanid, Quabodepistat |
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
BPaQ represents a pharmaceutical formulation strategy by Otsuka to enhance drug absorption and efficacy through prodrug technology. The exact active moiety and mechanism require further clinical characterization, but the approach aims to optimize pharmacokinetic properties for improved patient outcomes in its target indication.
Approved indications
Common side effects
Key clinical trials
- A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis (PHASE3)
- PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC) (NA)
- FES-Rowing: Preventing the Secondary Conditions of Paralysis Through Vigorous Exercise
- Effects of a 12-week Home-based Yoga on Bone and Cardiovascular Health (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPaQ CI brief — competitive landscape report
- BPaQ updates RSS · CI watch RSS
- Otsuka Pharmaceutical Development & Commercialization, Inc. portfolio CI